Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Lymphoma, Large B-Cell, Diffuse 12Burkitt Lymphoma 8Lymphoma, Follicular 7Sarcoma 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 5Neoplasms 4Lymphoma 4Wilms Tumor 3Sarcoma, Ewing 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Lymphoma, B-Cell 3Liposarcoma 3Endometrial Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2Down Syndrome 2Dermatofibrosarcoma 2

Interventions

Bevacizumab 12olaparib 10Paclitaxel 10Carboplatin 10liposomal doxorubicin 7Specimen Handling 7Magnetic Resonance Spectroscopy 6mirvetuximab soravtansine 4Topotecan 4Taxes 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Biopsy 4pembrolizumab 3cediranib 3Oxaliplatin 2Doxorubicin 21-dodecylpyridoxal 2tremelimumab 1trastuzumab deruxtecan 1sotorasib 1sarilumab 1palbociclib 1niraparib 1nilotinib 1neratinib 1irinotecan sucrosofate 1ipatasertib 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Doxorubicin × 30 days × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02839707 2026-06-01

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
444 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡